We are live on ! Find out more
LMAT icon

LeMaitre Vascular

297 hedge funds and large institutions have $1.73B invested in LeMaitre Vascular in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 108 increasing their positions, 114 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 26

1.26% more ownership

Funds ownership: 92.67%93.93% (+1.3%)

0% more funds holding

Funds holding: 297297 (0)

5% less repeat investments, than reductions

Existing positions increased: 108 | Existing positions reduced: 114

6% less capital invested

Capital invested by funds: $1.84B → $1.73B (-$107M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $219K

Holders
297
Holders Change
Holders Change %
0%
% of All Funds
3.59%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
30
Increased
108
Reduced
114
Closed
26
Calls
Puts
$219K
Net Calls
-$219K
Net Calls Change
-$709K

LMAT Hedge Fund Activity: Q4 2025 in Review

297 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in LeMaitre Vascular (LMAT) for Q4 2025, worth a combined $1.73B — down 5.9% from $1.84B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new LMAT positions and 26 closed out — a net gain of 4 holders — while 108 added to existing stakes and 114 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $19.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $20.5M.

  • 297 institutional investors held LeMaitre Vascular (LMAT) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $1.73B of LeMaitre Vascular stock for Q4 2025, down 5.9% quarter-over-quarter.
  • 30 funds opened new LeMaitre Vascular positions in Q4 2025 and 26 closed out, a net change of +4 holders.
  • The largest LeMaitre Vascular buyer in Q4 2025 was Goldman Sachs, an estimated $19.9M added.
  • The largest LeMaitre Vascular seller in Q4 2025 was T. Rowe Price Associates, an estimated $20.5M sold.

Based on aggregated 13F filings for Q4 2025.